Apoptosis-associated protein expression in PRED, VCR, and ASP (PVA)-sensitive and -resistant childhood ALL patients
Apoptotic protein . | PVA-sensitive patients, median AU (range) . | PVA-resistant patients, median AU (range) . | P . |
|---|---|---|---|
| Apaf-1TBLFN1 | 21.6 (12.7-124.4) | 17.4 (4.0-175.3) | .529TBLFN2 |
| Procaspase-2 | 13.4 (1.1-27.2) | 6.2 (1.2-10.1) | .019 |
| Procaspase-3 | 18.5 (9.9-41.0) | 20.8 (8.0-35.7) | .912 |
| Procaspase-6 | 17.5 (11.0-78.8) | 25.2 (16.3-49.0) | .280 |
| Procaspase-7 | 10.8 (6.1-32.4) | 8.6 (1.0-25.2) | .247 |
| Procaspase-8 | 32.4 (21.5-75.2) | 42.3 (17.0-110.1) | .393 |
| Procaspase-10 | 5.4 (0.0-40.8) | 6.4 (0.0-47.0) | .912 |
| PARP | 35.8 (6.5-48.9) | 15.1 (0.0-38.5) | .042 |
Apoptotic protein . | PVA-sensitive patients, median AU (range) . | PVA-resistant patients, median AU (range) . | P . |
|---|---|---|---|
| Apaf-1TBLFN1 | 21.6 (12.7-124.4) | 17.4 (4.0-175.3) | .529TBLFN2 |
| Procaspase-2 | 13.4 (1.1-27.2) | 6.2 (1.2-10.1) | .019 |
| Procaspase-3 | 18.5 (9.9-41.0) | 20.8 (8.0-35.7) | .912 |
| Procaspase-6 | 17.5 (11.0-78.8) | 25.2 (16.3-49.0) | .280 |
| Procaspase-7 | 10.8 (6.1-32.4) | 8.6 (1.0-25.2) | .247 |
| Procaspase-8 | 32.4 (21.5-75.2) | 42.3 (17.0-110.1) | .393 |
| Procaspase-10 | 5.4 (0.0-40.8) | 6.4 (0.0-47.0) | .912 |
| PARP | 35.8 (6.5-48.9) | 15.1 (0.0-38.5) | .042 |
Expression of 8 apoptotic proteins was compared in 10 PVA-sensitive (8 B-lineage ALL, 2 T-lineage ALL) and 10 PVA-resistant (5 B-lineage, 5 T-lineage) patients. For both groups, n = 10.
The expression of the predominantly expressed isoform was examined for all proteins.
Expression of an apoptotic protein in patient samples related to the expression of protein in a dilution series of the Reh leukemic cell line; see “Materials and methods.”